Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

SLFN11 (Schlafen Family Member 11)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

SLFN11 expression	Small Cell Lung Cancer	SLFN11 expression	Small Cell Lung Cancer	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3	ABT-888 Sensitive: C3 – Early Trials ABT-888 Sensitive : C3
SLFN11 expression	Myelodysplastic Syndrome	SLFN11 expression	Myelodysplastic Syndrome	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
SLFN11 expression	Acute Myelogenous Leukemia	SLFN11 expression	Acute Myelogenous Leukemia	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3	BGB324 Sensitive: C3 – Early Trials BGB324 Sensitive : C3
SLFN11 expression	Small Cell Lung Cancer	SLFN11 expression	Small Cell Lung Cancer	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3	temozolomide + ABT-888 Sensitive: C3 – Early Trials temozolomide + ABT-888 Sensitive : C3
SLFN11 overexpression	Soft Tissue Sarcoma	SLFN11 overexpression	Soft Tissue Sarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
SLFN11 expression	Esophageal Squamous Cell Carcinoma	SLFN11 expression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials cisplatin + 5-fluorouracil Sensitive : C3
SLFN11 elevation	Hepatocellular Cancer	SLFN11 elevation	Hepatocellular Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
SLFN11 expression	Small Cell Lung Cancer	SLFN11 expression	Small Cell Lung Cancer	atezolizumab + talazoparib Sensitive: C3 – Early Trials atezolizumab + talazoparib Sensitive : C3	atezolizumab + talazoparib Sensitive: C3 – Early Trials atezolizumab + talazoparib Sensitive : C3
SLFN11 expression	Acute Lymphocytic Leukemia	SLFN11 expression	Acute Lymphocytic Leukemia	nedaplatin Sensitive: D – Preclinical nedaplatin Sensitive : D	nedaplatin Sensitive: D – Preclinical nedaplatin Sensitive : D
SLFN11 expression	Acute Lymphocytic Leukemia	SLFN11 expression	Acute Lymphocytic Leukemia	carboplatin Sensitive: D – Preclinical carboplatin Sensitive : D	carboplatin Sensitive: D – Preclinical carboplatin Sensitive : D
SLFN11 expression	Small Cell Lung Cancer	SLFN11 expression	Small Cell Lung Cancer	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D	talazoparib Sensitive: D – Preclinical talazoparib Sensitive : D
SLFN11 overexpression	Small Cell Lung Cancer	SLFN11 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D